SIGLEC1 and neoplasm: With tumor progression, the functions of CD169+ macrophages that line the SCS and scavenge extracellular vesicles secreted by tumors that accumulate within TdLNs are also compromised, allowing vesicles to gain deeper access to the LN and interact with B cells to initiate tumor-promoting humoral immunity (126).